MichaelAnthonyCarducciMD

AEGON Professor of Prostate Cancer Research, Associate Director for Clinical Research, Member, Miller-Coulson Academy of Clinical Excellence

Join to view full profile

Dr. Carducci is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Carducci's full profile

Already have an account?

Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-367-2194

Summary

Dr. Michael Carducci is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center, and Sibley Memorial Hospital. He received his medical degree from Wayne State University School of Medicine and has been in practice 29 years. He specializes in hematologic oncology and is experienced in urologic oncology, and palliative medicine.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1992 - 1995
University of ColoradoResidency, Internal Medicine, 1988 - 1992
Wayne State University School of MedicineClass of 1988

Certifications & Licensure

DC State Medical License 2012 - 2027
MD State Medical License 1992 - 2026
VA State Medical License 2022 - 2026
CO State Medical License 1990 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma Start of enrollment: 1997 Feb 01
Completed
Phase 1
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment Start of enrollment: 2000 Mar 01
Completed
Phase 1
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer Start of enrollment: 2002 Apr 25
Completed
Phase 2
DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2001 Apr 01
Unknown status
Phase 2
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer Start of enrollment: 2003 Oct 08
Completed
Phase 3
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer Start of enrollment: 2003 Jul 14
Completed
Phase 2
Simultaneous Care: Linking Palliation to Clinical Trials Start of enrollment: 2002 Feb 01
Completed
Not Applicable
Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer Start of enrollment: 2006 Aug 01
Completed
Phase 1, Phase 2
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy Start of enrollment: 2009 Feb 01
Completed
Not Applicable
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2008 Jul 01
Withdrawn
Phase 2
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Oct 29
Active, not recruiting
Phase 1, Phase 2
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2010 Feb 06
Completed
Phase 1
Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer Start of enrollment: 2010 Feb 01
Completed
Phase 2
Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA) Start of enrollment: 2010 May 01
Completed
Not Applicable
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2011 Mar 01
Completed
Phase 3
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 1
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2014 Jan 23
Completed
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Start of enrollment: 2015 Mar 28
Active, not recruiting
Phase 2
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin Start of enrollment: 2017 Mar 21
Terminated
Phase 1
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma Start of enrollment: 2017 Jun 12
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2020 Jul 07
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Efficacy and Toxicity of [Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase ...
Vishnu Murthy, Andrew F Voter, Kathleen Nguyen, Martin Allen-Auerbach, Lucia Chen
Journal of Nuclear Medicine. 2024-11-01
Initial Experience with [Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
Andrei Gafita, Andrew Voter, Somya Shesadri, Avery Spitz, Catherine H Marshall
Journal of Nuclear Medicine. 2024-11-01
Correction: Behavioral Weight Loss Programs for Cancer Survivors Throughout Maryland: Protocol for a Pragmatic Trial and Participant Characteristics.
Gerald J Jerome, Lawrence J Appel, Linda Bunyard, Arlene T Dalcin, Nowella Durkin
JMIR Research Protocols. 2024-10-07

Other

Investigational approaches for the treatment of advanced prostate cancer
Carducci MA, Antonarakis ES, Walczak JR, Pili R
http://www.uptodate.com/contents/investigational-approaches-for-the-treatment-of-advanced-prostate-c
UpToDate, Wolters Kluwer Health - 2013-04-10

Press Mentions

Intervention to Improve Patient-Physician Communication May Improve Black Patient Participation in Clinical Trials, Study Led by Karmanos ResearcherFebruary 27th, 2023
Dramatic Results Seen with Bone-Protecting Agents in Prostate Cancer PatientsJune 5th, 2019
Trials Back Earlier Use of Androgen Receptor InhibitorsJune 3rd, 2019
Join now to see all

Grant Support

Phase I Clinical Trials Of New Anti-Cancer Targeted TherapiesNational Cancer Institute2008–2012
DSMNational Cancer Institute2006–2010
Phase I Clinical Trials Of New Anti-Cancer Targeted TherNational Cancer Institute2003–2007
Foreign Accrual For U01ca70095 - 2006 Load.National Cancer Institute2006
Restoration Of Gene Function In Prostate CancerNational Cancer Institute2003
Phase I Trials Of Anticancer AgentsNational Cancer Institute2001–2002
Phase I Trial Of Oral Phenylbutyrate In Solid TumorsNational Center For Research Resources2000–2002
Dose/Pharmacokinetics Of ABT 627 In AdenocarcinomaNational Center For Research Resources2000–2002
Multiple Dose Study Of Safety Of ABT 627National Center For Research Resources1998–2002
A Randomized Controlled Phase II Clinical Trial Of ModulDivision Of Cancer Prevention And Control1999–2000
Phenylbutyrate Bioactivity Assessment In Prostate CancerNational Cancer Institute1997–2000
Gene Therapy For Prostate CancerNational Cancer Institute1996–2000
Continuous Infusion Phenylbutyrate Given For 120 HRS Every 21 DaysNational Center For Research Resources1997